Vectus Biosystems Ltd Market Cap ($2.65 Million)
Market Cap & Net Worth: Vectus Biosystems Ltd (VBS)
Vectus Biosystems Ltd market cap. Vectus Biosystems Ltd (AU:VBS) has a market capitalization of $2.65 Million (AU$3.74 Million) as of November 8, 2026. Listed on the AU stock exchange, this Australia-based company holds position #29633 globally and #1672 in its home market, demonstrating a -22.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vectus Biosystems Ltd's stock price AU$0.07 by its total outstanding shares 53433331 (53.43 Million). Also see Vectus Biosystems Ltd (VBS) cash conversion ratio for how efficiently the company converts equity into cash flow.
Vectus Biosystems Ltd Market Cap History (2016–2026)
Vectus Biosystems Ltd market cap history from 2016 to 2026. Data shows change from $59.74 Million to $2.65 Million (-25.12% CAGR). Check latest Vectus Biosystems Ltd stock price today for real-time trading data and today's change.
Vectus Biosystems Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vectus Biosystems Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Vectus Biosystems Ltd growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
14.23x
Vectus Biosystems Ltd's market cap is 14.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $59.74 Million | $75.07K | -$3.21 Million | 795.78x | N/A |
| 2017 | $51.04 Million | $49.34K | -$3.79 Million | 1034.52x | N/A |
| 2018 | $22.31 Million | $1.83K | -$2.59 Million | 12209.31x | N/A |
| 2019 | $22.31 Million | $220.00 | -$1.60 Million | 101392.80x | N/A |
| 2020 | $45.37 Million | $51.19K | -$3.00 Million | 886.36x | N/A |
| 2021 | $53.31 Million | $180.00 | -$3.86 Million | 296158.64x | N/A |
| 2022 | $27.60 Million | $1.30 Million | -$3.99 Million | 21.23x | N/A |
| 2023 | $11.34 Million | $1.35 Million | -$3.45 Million | 8.37x | N/A |
| 2024 | $2.91 Million | $1.14 Million | -$2.34 Million | 2.56x | N/A |
| 2025 | $6.81 Million | $478.18K | -$1.78 Million | 14.23x | N/A |
Competitor Companies of VBS by Market Capitalization
Companies near Vectus Biosystems Ltd in the global market cap rankings as of November 8, 2026. Also see VBS asset base for a full breakdown of the balance sheet.
Key companies related to Vectus Biosystems Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Vectus Biosystems Ltd (2016–2026)
Market capitalization of Vectus Biosystems Ltd from 2016 to today. Between 2016 and today, Vectus Biosystems Ltd's market cap moved from $59.74 Million to $ 2.65 Million, with a yearly change of -25.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$2.65 Million | -61.11% |
| 2025 | AU$6.81 Million | +133.77% |
| 2024 | AU$2.91 Million | -74.33% |
| 2023 | AU$11.34 Million | -58.90% |
| 2022 | AU$27.60 Million | -48.23% |
| 2021 | AU$53.31 Million | +17.50% |
| 2020 | AU$45.37 Million | +103.39% |
| 2019 | AU$22.31 Million | 0.00% |
| 2018 | AU$22.31 Million | -56.30% |
| 2017 | AU$51.04 Million | -14.56% |
| 2016 | AU$59.74 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Vectus Biosystems Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.65 Million USD |
| MoneyControl | $2.65 Million USD |
| MarketWatch | $2.65 Million USD |
| marketcap.company | $2.65 Million USD |
| Reuters | $2.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more